David G McLeod
Overview
Explore the profile of David G McLeod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chand N, Tekumalla P, Rosenberg M, Dobi A, Ali A, Miller G, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398103
Prostate cancer represents a significant health risk to aging men, in which diagnostic challenges to the identification of aggressive cancers remain unmet. Prostate cancer screening is driven by the prostate-specific...
2.
Gesztes W, Schafer C, Young D, Fox J, Jiang J, Chen Y, et al.
Sci Rep
. 2022 Mar;
12(1):5404.
PMID: 35354846
TP53 is one of the most frequently altered genes in prostate cancer. The precise assessment of its focal alterations in primary tumors by immunohistochemistry (IHC) has significantly enhanced its prognosis....
3.
Kiebish M, Tekumalla P, Ravipaty S, Dobi A, Srivastava S, Wu W, et al.
Sci Rep
. 2021 Jul;
11(1):15052.
PMID: 34302010
Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated...
4.
Marshall C, Chen Y, Kuo C, Cullen J, Jiang J, Rosner I, et al.
J Urol
. 2021 May;
206(3):623-629.
PMID: 34003011
Purpose: There were 3 recent U.S. Food and Drug Administration approvals for drugs to be used in nonmetastatic castration resistant prostate cancer, a state that arises from the unproven start...
5.
Sharad S, Allemang T, Li H, Nousome D, Ku A, Whitlock N, et al.
Front Oncol
. 2021 Feb;
10:584280.
PMID: 33575208
Prostate cancer incidence in young men has increased. Patients diagnosed at an earlier age are likely to have aggressive prostate cancer and treatment decisions are continuing to be weighted by...
6.
Tan S, Young D, Chen Y, Kuo H, Srinivasan A, Dobi A, et al.
Pathology
. 2020 Sep;
53(2):205-213.
PMID: 32967771
ANXA2 (Annexin A2 or Annexin II) is a calcium dependent phospholipid binding protein with diverse cellular functions. While ANXA2 is either absent or expressed focally in the prostate epithelium of...
7.
Higano C, Armstrong A, Sartor O, Vogelzang N, Kantoff P, McLeod D, et al.
Cancer
. 2020 Mar;
126(12):2935-2937.
PMID: 32154908
No abstract available.
8.
Sartor O, Armstrong A, Ahaghotu C, McLeod D, Cooperberg M, Penson D, et al.
Prostate Cancer Prostatic Dis
. 2020 Mar;
23(3):517-526.
PMID: 32111923
Purpose: African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences in overall survival (OS) between African American and...
9.
Kiebish M, Cullen J, Mishra P, Ali A, Milliman E, Rodrigues L, et al.
J Transl Med
. 2020 Jan;
18(1):10.
PMID: 31910880
Background: Predicting the clinical course of prostate cancer is challenging due to the wide biological spectrum of the disease. The objective of our study was to identify prostate cancer prognostic...
10.
Yan W, Jamal M, Tan S, Song Y, Young D, Chen Y, et al.
Oncotarget
. 2019 Nov;
10(60):6466-6483.
PMID: 31741711
Background: As a major cause of morbidity and mortality among men, prostate cancer is a heterogenous disease, with a vast heterogeneity in the biology of the disease and in clinical...